| pubmed-article:16160401 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16160401 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16160401 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:16160401 | lifeskim:mentions | umls-concept:C0014544 | lld:lifeskim |
| pubmed-article:16160401 | lifeskim:mentions | umls-concept:C0017638 | lld:lifeskim |
| pubmed-article:16160401 | pubmed:issue | 8-9 | lld:pubmed |
| pubmed-article:16160401 | pubmed:dateCreated | 2005-9-14 | lld:pubmed |
| pubmed-article:16160401 | pubmed:abstractText | The risk for patients with primary brain tumors of experiencing an epileptic seizure at least once in the course of disease probably exceeds 50%, depending on tumor location and tumor type. Several aspects regarding the role of anticonvulsants in the treatment of brain tumor patients have remained controversial. | lld:pubmed |
| pubmed-article:16160401 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16160401 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16160401 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16160401 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16160401 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16160401 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16160401 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16160401 | pubmed:issn | 0378-584X | lld:pubmed |
| pubmed-article:16160401 | pubmed:author | pubmed-author:WellerMichael... | lld:pubmed |
| pubmed-article:16160401 | pubmed:author | pubmed-author:MeisnerChrist... | lld:pubmed |
| pubmed-article:16160401 | pubmed:author | pubmed-author:TatagibaMarco... | lld:pubmed |
| pubmed-article:16160401 | pubmed:author | pubmed-author:WickWolfgangW | lld:pubmed |
| pubmed-article:16160401 | pubmed:author | pubmed-author:HermissonMirj... | lld:pubmed |
| pubmed-article:16160401 | pubmed:author | pubmed-author:MennOliverO | lld:pubmed |
| pubmed-article:16160401 | pubmed:author | pubmed-author:SteinbachJoac... | lld:pubmed |
| pubmed-article:16160401 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16160401 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:16160401 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16160401 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16160401 | pubmed:pagination | 391-6 | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:meshHeading | pubmed-meshheading:16160401... | lld:pubmed |
| pubmed-article:16160401 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16160401 | pubmed:articleTitle | Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? | lld:pubmed |
| pubmed-article:16160401 | pubmed:affiliation | Abteilung für Allgemeine Neurologie, Hertie-Institut für Klinische Hirnforschung, Zentrum für Neurologie, Universitatsklinikum Tübingen, Germany. wolfgang.wick@uni-tuebingen.de | lld:pubmed |
| pubmed-article:16160401 | pubmed:publicationType | Journal Article | lld:pubmed |
